IRB #

STUDY00017104

Title

DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

Principal Investigator

John Vetto

Study Purpose

The DecisionDx-Melanoma gene expression assay (test) evaluates the genetic makeup of tumor tissue and classifies it as low risk (Class 1) or high risk (Class 2) for spreading to other areas of the body. This study is being done to collect information about how physicians are using the DecisionDx-Melanoma results to design individual treatment plans.

Medical Condition(s)

Cutaneous melanoma (melanoma of the skin)

Eligibility Criteria

1. Newly diagnosed stage I-III cutaneous melanoma patients for whom the physician has determined the DecisionDx-Melanoma test to be medically necessary for treatment management guidance.
2. Male and female patients > 18 Years of age.
3. Patient must speak and read English and be able to give informed consent.

Other criteria may apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Patients will visit their physician as often as he/she feels necessary for routine care. There are no study-related visits required. Participation in the study will last up to 6 months.

Minors Included

No

Contact

Knight Clinical Trials
503-494-1080

Sponsor

Castle Biosciences, Inc.

Recruitment End

12/31/2020

Compensation Provided

No


Go Back